目的:本研究旨在调查暴露于异维A酸(ISO)治疗痤疮的个体的嗅觉功能障碍的患病率和相关因素。使用宾夕法尼亚大学气味识别测试(UPSIT®)。
方法:这项横断面研究纳入了年龄和性别匹配的痤疮患者,这些患者目前是口服ISO和未暴露的对照组,没有嗅觉投诉。使用UPSIT®和经过验证的问卷(鼻塞症状评估)来评估暴露于ISO的患者的鼻塞。
结果:共招募了70名患者,暴露组35人,未暴露组35人,每组由18名男性和17名女性组成,年龄从17岁到47岁。暴露组的嗅觉功能障碍患病率高于非暴露组(62.9%vs.17.1%),患病率(PR)为3.7(95%CI1.9-7.1)。然而,没有参与者被归类为嗅觉缺失或严重的失血,与中度失血相比,大多数功能障碍是轻度失血(51.5%vs.11.4%)。在暴露的个体中,汽油,橙色,咖啡,木材的识别错误率最高(≥54%)。嗅觉功能与治疗时间呈负相关(p=0.01),累积剂量(p=0.02),鼻塞(p=0.02)。
结论:嗅觉功能障碍在ISO用户中更为普遍,尽管患者没有意识到这种疾病。嗅觉变化与治疗持续时间相关,累积剂量,还有鼻塞.
方法:第4级。
OBJECTIVE: This study aimed to investigate the prevalence and factors associated with olfactory dysfunction in individuals exposed to Isotretinoin (ISO) for the treatment of acne, using the University of Pennsylvania Smell Identification Test (UPSIT®).
METHODS: This cross-sectional study enrolled age and sex-matched patients with acne who were current users of oral ISO and unexposed controls without olfactory complaints. UPSIT® and a validated questionnaire (Nasal Obstruction Symptom Evaluation) were administered to evaluate nasal obstruction in patients exposed to ISO.
RESULTS: A total of seventy patients were recruited, with 35 in the exposed group and 35 in the unexposed group, consisting of 18 males and 17 females in each group, aged from 17 to 47 years. The prevalence of olfactory dysfunction was higher in the exposed group compared to the non-exposed group (62.9% vs. 17.1%), yielding a Prevalence Ratio (PR) of 3.7 (95% CI 1.9-7.1). However, no participants were categorized as anosmia or severe hyposmia and the majority of dysfunction was mild hyposmia compared to moderate hyposmia (51.5% vs. 11.4%). Among the exposed individuals, gasoline, orange, coffee, and wood exhibited the highest rates of identification errors (≥54%). Olfactory function demonstrated a negative correlation with treatment duration (p = 0.01), cumulative dose (p = 0.02), and nasal obstruction (p = 0.02).
CONCLUSIONS: Olfactory dysfunction was more prevalent among ISO users, despite the patients being unaware of the disorder. Olfactory changes were correlated with treatment duration, cumulative dose, and nasal obstruction.
METHODS: Level 4.